DMAC (DiaMedica Therapeutics) Cyclically Adjusted FCF per Share: $-0.75 (As of Mar. 2026)


DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $7.45
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Cyclically Adjusted FCF per Share?

DiaMedica Therapeutics DMAC +5.53% 31 Cyclically Adjusted FCF per Share is $-0.75 as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

DiaMedica Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.169. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.75 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 8.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.90% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of DiaMedica Therapeutics was 14.80% per year. The lowest was 6.00% per year. And the median was 10.00% per year.

As of today (2026-07-02), DiaMedica Therapeutics's current stock price is $7.445. DiaMedica Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.75. DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


DiaMedica Therapeutics  (NAS:DMAC) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


DiaMedica Therapeutics Cyclically Adjusted FCF per Share Related Terms


DiaMedica Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Cyclically Adjusted FCF per Share Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.15 -0.98 -0.80 -0.71 -0.74

DiaMedica Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.72 -0.73 -0.74 -0.74 -0.75

DMAC vs PRLD, RCKT, TENX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DiaMedica Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where DiaMedica Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, DiaMedica Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.169/330.2130*330.2130
=-0.169

Current CPI (Mar. 2026) = 330.2130.

DiaMedica Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.090 241.018 -0.123
201609 -0.194 241.428 -0.265
201612 -0.229 241.432 -0.313
201703 -0.149 243.801 -0.202
201706 -0.239 244.955 -0.322
201709 -0.112 246.819 -0.150
201712 -0.157 246.524 -0.210
201803 -0.148 249.554 -0.196
201806 -0.132 251.989 -0.173
201809 -0.237 252.439 -0.310
201812 -0.216 251.233 -0.284
201903 -0.262 254.202 -0.340
201906 -0.240 256.143 -0.309
201909 -0.103 256.759 -0.132
201912 -0.155 256.974 -0.199
202003 -0.227 258.115 -0.290
202006 -0.060 257.797 -0.077
202009 -0.141 260.280 -0.179
202012 -0.161 260.474 -0.204
202103 -0.230 264.877 -0.287
202106 -0.111 271.696 -0.135
202109 -0.160 274.310 -0.193
202112 -0.106 278.802 -0.126
202203 -0.147 287.504 -0.169
202206 -0.094 296.311 -0.105
202209 -0.089 296.808 -0.099
202212 -0.105 296.797 -0.117
202303 -0.193 301.836 -0.211
202306 -0.184 305.109 -0.199
202309 -0.127 307.789 -0.136
202312 -0.100 306.746 -0.108
202403 -0.176 312.332 -0.186
202406 -0.119 314.175 -0.125
202409 -0.105 315.301 -0.110
202412 -0.150 315.605 -0.157
202503 -0.167 319.799 -0.172
202506 -0.177 322.561 -0.181
202509 -0.132 324.800 -0.134
202512 -0.148 324.054 -0.151
202603 -0.169 330.213 -0.169

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.75 mean?
DiaMedica Therapeutics (DMAC) has a Cyclically Adjusted FCF per Share of $-0.75 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Cyclically Adjusted FCF per Share too high?
DiaMedica Therapeutics' current Cyclically Adjusted FCF per Share is $-0.75. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Cyclically Adjusted FCF per Share compare to PRLD and RCKT?
DiaMedica Therapeutics' Cyclically Adjusted FCF per Share of $-0.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Cyclically Adjusted FCF per Share is $-0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Cyclically Adjusted FCF per Share of $-0.75. The current Cyclically Adjusted FCF per Share is $-0.75. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Cyclically Adjusted FCF per Share is $-0.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price